Adaptimmune Therapeutics plc has announced new compensation agreements following the termination of several key executives due to redundancy. Dr. Elliot Norry, formerly the Chief Medical Officer, will receive a severance payment equivalent to 12 months of his 2025 base salary, totaling $478,135, along with a COBRA healthcare coverage payment of $30,965.73. Dr. Joanna Brewer, the outgoing Chief Scientific Officer, will receive £344,844 (approximately $460,639) as a severance payment, with an option for healthcare benefits reimbursement for a year. Gavin Wood, the former Chief Financial Officer, will be compensated with a 12-month base salary payment and a potential pro rata bonus of £111,417 (approximately $148,830), alongside healthcare benefits reimbursement for 12 months post-termination. All three executives have been granted a 12-month period to exercise their vested Market Value Options, in accordance with the company's 2016 Share Option Scheme.